Dr. Daniel Norman, M.D.
Sleep Medicine (Sleep Medicine (Internal Medicine) Physician)
12301 Wilshire Blvd Ste 200
Los Angeles, CA 90025
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Irvine, California College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,261
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of California, Irvine, California College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Sleep Medicine (Internal Medicine) Physician primary
CA license A86203 (first issued 2004; current) -
Critical Care Medicine (Internal Medicine) Physician
CA license A86203 (first issued 2004; current) -
Internal Medicine Physician
CA license A86203 (first issued 2004; current) -
Pulmonary Disease Physician
CA license A86203 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Daniel Norman, M.d., Inc. (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,261
- Services billed
- 2,491
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 985 | 684 |
| Established patient office or other outpatient visit, 20-29 minutes | 362 | 304 |
| New patient office or other outpatient visit, 45-59 minutes | 298 | 298 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 249 | 241 |
| Therapy procedure using a positive pressure ventilator | 161 | 128 |
| Sleep study in sleep lab (6 years or older) | 118 | 116 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 91 | 90 |
| New patient office or other outpatient visit, 30-44 minutes | 47 | 47 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 38 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mirtazapine Other prescribers in Los Angeles, CA | 63 |
| Dayvigo (lemborexant) | 54 |
| Trazodone Hcl Other prescribers in Los Angeles, CA | 40 |
| Azelastine Hcl Other prescribers in Los Angeles, CA | 40 |
| Zolpidem Tartrate Other prescribers in Los Angeles, CA | 38 |
| Belsomra (suvorexant) Other prescribers in Los Angeles, CA | 37 |
| Modafinil Other prescribers in Los Angeles, CA | 33 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Los Angeles, CA | 24 |
| Quviviq (daridorexant hcl) | 24 |
| Fluticasone Propionate Other prescribers in Los Angeles, CA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 63 payments worth $2,063 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $575 |
|---|---|
| Harmony Biosciences LLC | $564 |
| Inspire Medical Systems, Inc. | $390 |
| Avadel Cns Pharmaceuticals, LLC | $258 |
| Axsome Therapeutics, Inc. | $143 |
| Lilly USA, LLC | $133 |
| Food and Beverage | $2,063 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $1,327,855 in research payments for these studies, mostly to the institutions running them.
- Tradipitant - GLP-1R agonist-induced nausea and vomiting
Vanda Pharmaceuticals Inc. - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Alkermes, Inc. · Completed · NCT06555783 - A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Y…
Jazz Pharmaceuticals Inc. - Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Avadel Cns Pharmaceuticals, LLC · Completed · NCT06525077 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Alkermes, Inc. · Completed · NCT06358950 - A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. · Recruiting · NCT06767683 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590 - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Vanda Pharmaceuticals Inc. - Evaluating the effects oftasimelteonin individuals with autism spectrum disorder (asd) and sleep disturbances
Vanda Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.